Cardiovascular Disease in Adult and Pediatric HIV/AIDS  by McDonald, Cheryl L. & Kaltman, Jonathan R.
Journal of the American College of Cardiology Vol. 54, No. 13, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2009.05.055
News thefromNHLBI
Cardiovascular Disease
in Adult and Pediatric HIV/AIDS
Cheryl L. McDonald, MD, Jonathan R. Kaltman, MD
Bethesda, MarylandS
s
a
a
t
t
D
t
(
h
d
p
i
u
i
l
a
a
u
a
t
p
t
s
P
c
A
p
(
(
l
c
a
e
s
s
i
H
p
H
i
t
i
e
p
l
r
A
T
r
e
3
S
G
E
I
r
h
s
t
l
F
o
tince it was first recognized clinically in 1981, human
immunodeficiency virus (HIV)/acquired immunode-
ficiency syndrome (AIDS) has gone from a fatal
yndrome to a chronic disease in persons receiving highly
ctive antiretroviral therapy (HAART). Although the first
ntiretroviral agent, zidovudine (AZT), was introduced into
he market in 1987, the era of HAART really began after
he marketing approval of the first protease inhibitor in
ecember 1995. Much has been reported about the rela-
ionship between HAART and cardiovascular disease
CVD), but it is this combination antiretroviral therapy that
as allowed the overall mortality associated with HIV to
ecline dramatically and life expectancy to increase to the
oint where CVD-related deaths now represent an increas-
ng proportion of the deaths in HIV-infected patients.
Even before the era of HAART, researchers noted that
ntreated HIV-infected patients had altered lipid profiles,
ncluding lowered high-density lipoprotein and low-density
ipoprotein cholesterol levels, elevated triglyceride levels,
nd anthropomorphic changes such as increased visceral fat
nd decreased subcutaneous fat (1,2). With the widespread
se of HAART, the contribution of drug-related metabolic
nd anthropometric alterations to an increased risk for CVD
ook on an even greater significance. Several studies in adult
opulations have provided evidence of an association be-
ween HIV infection and its treatment and CVD; these
tudies include retrospective studies such as the Kaiser
ermanente Registry study (3), prospective observational
ohort studies such as the DAD (Data Collection of
dverse Events of Anti-HIV Drugs) study (4,5), and
rospective randomized clinical trials such as the SMART
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f Health, Bethesda, Maryland. Drs. McDonald and Kaltman are Medical Officers int
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Manuscript received April 23, 2009; accepted May 6, 2009.Strategies for Management of Antiretroviral Therapy) trial
6). Although myriad class- and nonclass-specific effects on
ipid profiles, glucose levels, insulin sensitivity, and body
omposition have been reported with various antiretroviral
gents, there is no question that the use of HAART to
nsure adequate viral suppression is paramount to the
uccessful clinical management of HIV-infected patients.
The currently available evidence from various studies
uggests that although the overall cardiovascular event rate
s low, there is an excess risk of cardiovascular events in
IV-infected persons compared with non–HIV-infected
ersons. Evidence suggests that HIV-infected patients on
AART regimens are at increased risk of dyslipidemia,
schemic heart disease (7), and myocardial infarction, par-
icularly if the HAART regimen contains a protease inhib-
tor (8,9). While lipid-lowering therapies are a routine
lement of cardiovascular risk reduction in the general
opulation, HIV-infected patients may not be receiving
ipid-lowering therapies even when indicated. A recent
eport showed that among patients meeting the NCEP
TP III (National Cholesterol Education Program Adult
reatment Panel III) criteria (10), there was a disparity in
eceipt of lipid-lowering agents among HIV-infected vet-
rans compared with non–HIV-infected veterans (15.4% vs.
7.9%, p  0.01) (11). In 2003, the Infectious Diseases
ociety of America and the Adult AIDS Clinical Trials
roup issued an updated version of “Guidelines for the
valuation and Management of Dyslipidemia in Human
mmunodeficiency Virus-Infected Adults Receiving Anti-
etroviral Therapy” (12). Patients infected with HIV may
ave special issues, such as coinfection with hepatitis C,
eemingly complicated medication regimens, unusually high
riglyceride levels, or the need to gain weight yet achieve
ower lipid levels; but, the approach to the management of
heir dyslipidemia is essentially the same as that for the general
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nondrug and dietary modalities. If
lipid-lowering agents are indi-
cated, navigating the sea of poten-
tial drug-drug interactions with
the HAART regimen can be chal-
lenging, but that should not pre-
clude the use of drugs such as
statins or fibrates for HIV-infected
patients. Getting to target low-
density lipoprotein goals can and
should be accomplished by a car-
diologist working closely with an
infectious diseases specialist (13).
Antiretroviral drugs are the
cornerstone of HIV/AIDS man-
agement, and they may be asso-
ciated with insulin resistance and
dyslipidemia, but those are not
the only factors likely involved in
he increased CVD risk seen in HIV-infected patients.
raditional risk factors, such as increased rates of smoking,
ay be increased in these patients; HIV itself may affect
raditional risk factors, including lipid profiles; and/or there
ay be increased underlying inflammation or endothelial
ysfunction. How HIV affects the heart and vasculature as
whole in the presence of antiretroviral therapy (ART) is
ot fully known, but left ventricular (LV) dysfunction is
linically common, and pulmonary arterial hypertension can
ccur in 1 of every 200 HIV-positive adults, most often in
atients without advanced HIV disease. In contrast to
rimary pulmonary hypertension (PPH), in which there is a
emale predominance, males are more affected by pulmonary
rterial hypertension (PAH) associated with HIV infection
HIV-PAH). Although HIV-PAH shares several clinical
nd pathological features with PPH, it has decreased 1-year
urvival rates (51%) compared to rates in a National Insti-
utes of Health registry for PPH (68%) (14). Patients with
IV-PAH have worse survival than do HIV-infected
atients without PAH and often die from conditions related
o the pulmonary hypertension, not the HIV infection per
e. Therefore, prompt diagnosis and initiation of specific
herapy such as a prostacyclin (epoprostenol) or the dual
ndothelin receptor antagonist bosentan is crucial (15).
solated diastolic dysfunction may be an early sign of CVD
n both the general population and HIV-infected patients.
recent, albeit small, study reported an unexpectedly high
revalence of diastolic dysfunction (37%) in a cohort of
oung (median age 38 years), asymptomatic HIV-infected
atients at otherwise low risk for CVD (16). Consequently,
lthough there are currently no recommendations for rou-
ine screening echocardiograms of this population, these
ata suggest such additional evaluations may be warranted
or particular patients.
Research conducted before the HAART era demon-
Abbreviations
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CVD  cardiovascular
disease
HAART  highly active
antiretroviral therapy
HIV/AIDS  human
immunodeficiency
virus/acquired
immunodeficiency syndrome
LV  left ventricular
NHLBI  National Heart,
Lung, and Blood Institute
PAH  pulmonary arterial
hypertension
PPH  primary pulmonary
hypertensiontrated that HIV infection itself can cause nonatheroscle- totic structural and functional injury to the heart and
asculature. In 1 of the first reports of cardiac disease in
IV-infected children, Lipshultz et al. (17) reported ab-
ormalities of LV shortening, afterload, and contractility.
ericardial effusion, arrhythmias, and pathologic evidence of
ericarditis, myocarditis, and inflammation of the conduc-
ion system were also observed. To address the high rates of
ardiac complications seen in the HIV/AIDS epidemic, the
ational Heart, Lung, and Blood Institute (NHLBI) ini-
iated the P2C2 HIV (Pediatric Pulmonary and Cardiac
omplications of Vertically Transmitted HIV Infection)
tudy in 1990 (18). The P2C2 HIV study was a prospective,
bservational study that enrolled HIV-infected children
rom 1990 to 1993 with follow-up to 10 years of age. The
tudy documented cardiac complications as a common feature
f HIV disease in children. The 5-year cumulative incidence of
epressed shortening fraction was 28%, the incidence of LV
nd-diastolic dilation was 22%, and the incidence of heart
ailure and/or use of cardiac medications was 29% (19).
ecreased LV shortening and increased LV wall thickness
ere found to be predictive of mortality even after adjusting for
D4 count and encephalopathy (20).
One of the great successes of HAART is the significant
ecrease in vertical transmission of HIV from mother to
hild, but this has led to an increasing cohort of ART-
xposed, HIV-negative children. Recent evidence suggests
n important role of ART exposure itself in contributing to
ardiac disease. The P2C2 HIV study documented dimin-
shed LV shortening and contractility at birth in HIV-
egative infants born to HIV-positive mothers, suggesting
hat the in utero environment plays an important role in
ostnatal cardiovascular function. Animal model data have
ubsequently indicated that nucleoside analog reverse tran-
criptase inhibitors have a toxic effect on mitochondrial
unction (21). Further, human studies have demonstrated a
epletion of mitochondrial DNA and elevated plasma
actate levels in HIV-negative infants born to zidovudine-
reated, HIV-positive mothers (22). Taken together, these
ata suggest potential cardiotoxic effects of ART exposure
n utero. Recently, more direct evidence for this associa-
ion was provided by the CHAART-I (Cardiac Status of
AART Exposed Infants of HIV-Infected Mothers) study,
n which serial echocardiograms from HIV-negative infants
orn to ART- or HAART-treated, HIV-positive mothers
ere compared to HIV-negative infants born to HIV-positive
others who did not receive perinatal ART or HAART. A
reliminary report from that study indicated that fetal
xposure to ART/HAART was associated with progressive
eductions in LV mass and septal wall thickness (23).
The NHLBI provides cofunding for the Eunice Kennedy
hriver National Institute of Child Health and Human
evelopment-sponsored PHACS (Pediatric HIV/AIDS
ohort Study) network (24). This network, established in
005, seeks to advance our understanding of the long-term
afety of fetal and infant exposure to prophylactic ART and
he effects of perinatally acquired HIV infection in adoles-
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ational cohort studies—the Surveillance Monitoring for
RT Toxicities (SMARTT) study and the Adolescent
aster Protocol (AMP) study—both with significant car-
iovascular components.
The SMARTT study (not to be confused with the
MART study in adults) follows the ART-exposed, but
IV-uninfected infants and children born to HIV-infected
others to evaluate them for conditions and diagnoses
otentially related to in utero and infantile exposure to
ntiretroviral therapies. The study will identify abnormali-
ies in cardiac function related to ART and/or HIV expo-
ure and examine the utility of serum biomarkers as surro-
ates of cardiac dysfunction.
The AMP cohort consists of perinatally exposed, HIV-
nfected children between the ages of 7 and 16 years and a
omparison group of perinatally exposed, HIV-uninfected
hildren. The goal of the study is to evaluate the impact of
IV infection and ART on pre-adolescents and adolescents
ith perinatal HIV infection. Cardiac function will be
valuated by echocardiography to estimate the prevalence of
tructural and functional abnormalities in this contemporary
ohort of HIV-infected youths.
Recently published work has demonstrated that, similar
o use in adults, the use of protease inhibitors in HIV-
nfected children is significantly correlated with elevated
riglyceride and low-density lipoprotein cholesterol levels
nd with reduced high-density lipoprotein cholesterol levels
25). What this means in terms of cardiovascular risk for
IV-infected children, in the face of life-long antiretroviral
herapy, is unknown.
A State of the Science Conference was convened in
hicago in June 2007 to examine the important unanswered
uestions surrounding the pathogenesis, detection, and
reatment of CVD in HIV-infected persons (26). After this
onference, the NHLBI issued a request for applications for
esearch into the mechanisms and management of cardio-
ascular and metabolic complications of HIV/AIDS. The
HLBI awarded grants to 8 primary research sites and a
linical coordinating center, representing a spectrum of
IV-infected patients and controls including men and
omen, children, persons with long-standing infection, and
ewly diagnosed and/or treatment-naïve patients. Some of
he areas under investigation in this program include the
ollowing: the role of oxidative stress and inflammation in
levated CVD risk; the effect of antiretroviral therapies on
ndothelial function and atherosclerosis progression; im-
une, inflammatory, coagulation, and lipid alterations as
ediators of increased atherosclerosis; and assessments of
ascular dysfunction due to HIV itself and metabolic pa-
ameters. The various studies include standard and novel
maging techniques as well as measurements of endothelial
unction. The awardees have worked together closely to
evelop a core set of, and standardized approaches to,
aboratory evaluations. The results from these studies are
ure to add to our knowledge of CVD and its management
1n HIV/AIDS, with the possibility for advancing our
nderstanding of CVD in general.
The NHLBI encourages the continued partnership of
asic and clinical cardiovascular and infectious diseases
esearchers in their effort to tackle the difficult and still
nanswered questions of CVD in HIV/AIDS.
eprint requests and correspondence: Dr. Cheryl L. McDonald,
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